Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.36 |
| ▸ | PADI2 | Q9Y2J8 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 7/20 | 0.33 |
| ▸ | NPY1R | P25929 | 6/20 | 0.33 |
| ▸ | NPY2R | P49146 | 3/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.33 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21546368 | 1.00 | PADI4 (0.36) | PADI4PADI2TDP1KDM1ANPY4R | |
| SCHEMBL17619962 | 0.91 | PADI4 (0.38) | PADI4PADI2PADI6 | |
| SCHEMBL17620047 | 0.91 | KDM4E (0.39) | PADI4NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL21546358 | 0.89 | NPY4R (0.35) | PADI4PADI2NPY4RNPY1RNPY2R | |
| SCHEMBL17620029 | 0.88 | MALT1 (0.36) | PADI4PADI2TDP1KDM1ANPY4R | |
| SCHEMBL17619932 | 0.83 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL17620032 | 0.83 | HRH4 (0.36) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL22260620 | 0.79 | GRIN1 (0.35) | PADI4PADI2NPY4RNPY1RNPY2R | |
| SCHEMBL17620030 | 0.79 | GRIN1 (0.35) | PADI4PADI2NPY4RNPY1RNPY2R | |
| SCHEMBL18591492 | 0.74 | KDM4E (0.34) | PADI4NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571409-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210340126-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-11-04 | — | — | US | disclosed |
| US-11059808-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210093608-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2021-04-01 | — | — | US | disclosed |
| US-10869856-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200231571-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-07-23 | — | — | US | disclosed |
| US-20200163935-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NEW YORK BLOOD CENTER, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10576059-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190343797-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NEW YORK BLOOD CENTER, INC. | 2019-11-14 | — | — | US | disclosed |
| US-10413527-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190070146-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2019-03-07 | — | — | US | disclosed |
| US-20170273943-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-09-28 | — | — | US | disclosed |
| WO-2017035127-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NEW YORK BLOOD CENTER, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2016044808-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NEW YORK BLOOD CENTER, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10576059-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | PADI4 1726/4885PADI2 2177/4885TDP1 2076/4885 |
| US-20210093608-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | PADI4 1726/4885PADI2 2177/4885TDP1 2076/4885 |
| US-10413527-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | PADI4 1726/4885PADI2 2177/4885TDP1 2076/4885 |
| US-10869856-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | PADI4 1726/4885PADI2 2177/4885TDP1 2076/4885 |
| US-20190070146-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | PADI4 1726/4885PADI2 2177/4885TDP1 2076/4885 |
| US-20200163935-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | PADI4 1726/4885PADI2 2177/4885TDP1 2076/4885 |
| US-20170273943-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | PADI4 1726/4885PADI2 2177/4885TDP1 2076/4885 |
| US-20200231571-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | PADI4 1726/4885PADI2 2177/4885TDP1 2076/4885 |
| US-20190343797-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | PADI4 1726/4885PADI2 2177/4885TDP1 2076/4885 |
| US-20210340126-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | PADI4 1726/4885PADI2 2177/4885TDP1 2076/4885 |
| US-11571409-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | PADI4 1726/4885PADI2 2177/4885TDP1 2076/4885 |
| US-11059808-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | PADI4 1726/4885PADI2 2177/4885TDP1 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.